Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Assunta Carpinelli is active.

Publication


Featured researches published by Assunta Carpinelli.


NeuroImage | 2008

In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder

Daniela Perani; Valentina Garibotto; Alessandra Gorini; Rosa Maria Moresco; Marta Henin; Andrea Panzacchi; Mario Matarrese; Assunta Carpinelli; Laura Bellodi; Ferruccio Fazio

There are several lines of evidence, the majority indirect, suggesting that changes in serotonergic or dopaminergic neurotransmission may contribute to the pathogenesis of obsessive-compulsive disorder (OCD). We evaluated the co-occurrence of serotonergic and dopaminergic dysfunctions in OCD subjects, all drug-naive, with no co-morbidity and homogeneous for symptoms. Each subject underwent two positron emission tomography (PET) scans to measure in vivo both serotonin (5-HT(2A)) and dopamine (D(2)) receptor distribution. For this, we used [11C]MDL and [11C]Raclopride, highly selective antagonists of 5-HT(2A) and D(2) receptors, respectively. The comparison with a control group was carried out using both voxel-wise (SPM2) and regions of interest (ROI) approaches. There was a significant reduction of 5-HT(2A) receptor availability in frontal polar, dorsolateral, and medial frontal cortex, as well as in parietal and temporal associative cortex of OCD patients. We also found a significant correlation between 5-HT(2A) receptor availability in orbitofrontal and dorsolateral frontal cortex and clinical severity, suggesting a specific role for serotonin in determining the OCD symptoms. There was also a significant reduction of [11C]Raclopride uptake in the whole striatum, particularly in the ventral portion, possibly reflecting endogenous dopaminergic hyperactivity. The co-existence of serotonergic and dopaminergic dysfunction in the same homogeneous group of drug-naive OCD patients provides in vivo evidence for the complex molecular mechanisms of OCD, and represents the basis for further studies on the effect of therapeutic agents with specific modulatory effects on these neurotransmission systems.


Neuroreport | 2005

Basal ganglia and language: phonology modulates dopaminergic release

Marco Tettamanti; Andrea Moro; Cristina Messa; Rosa Maria Moresco; Giovanna Rizzo; Assunta Carpinelli; Mario Matarrese; Ferruccio Fazio; Daniela Perani

Basal ganglia have been implicated in syntactic and phonological processes, but direct evidence has been scarce. Here, we used [11C]raclopride and positron emission tomography to measure modulations of the dopaminergic system induced by phonological or syntactic processing. Two significant effects were found. First, the level of accuracy in phonological processing significantly correlated with tracer binding potential in the left caudate nucleus. Second, the speed in phonological processing significantly correlated with tracer binding potential in the left putamen. Thus, a more accurate and fast phonological processing was associated with a reduced dopamine requirement in the left striatum. These findings show that the striatal dopaminergic system plays an essential role in grammatical processes that form the core of human language.


Neuropsychopharmacology | 2007

Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients.

Rosa Maria Moresco; Lucia Pietra; Marta Henin; Andrea Panzacchi; Marco Locatelli; Lorena Bonaldi; Assunta Carpinelli; Clara Gobbo; Laura Bellodi; Daniela Perani; Ferruccio Fazio

Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naïve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p<0.01) to values closer to those observed in the group of normal subjects. Chronic treatment with fluvoxamine induces a slight but significant increase in striatal [11C]Rac BP of previously drug-naïve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.


Movement Disorders | 2011

In Vivo Evidence for GABAA Receptor Changes in the Sensorimotor System in Primary Dystonia

Valentina Garibotto; Luigi Romito; Antonio E. Elia; Paola Soliveri; Andrea Panzacchi; Assunta Carpinelli; Michele Tinazzi; Alberto Albanese; Daniela Perani

Preclinical and clinical evidence suggests that impaired gamma‐aminobutyric (GABA) control, leading to disinhibition within the sensorimotor system, might play a role in dystonia. Aim of this study is the in vivo assessment of the GABAergic system in dystonia using positron emission tomography (PET) and 11C‐flumazenil, a selective GABAA receptor ligand.


Neurobiology of Disease | 2008

A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset.

Andrea Panzacchi; Rosa Maria Moresco; Valentina Garibotto; Angelo Antonini; C. Gobbo; Ioannis U. Isaias; Stefano Goldwurm; Lorena Bonaldi; Assunta Carpinelli; Gianni Pezzoli; Ferruccio Fazio; Daniela Perani

We used positron emission tomography (PET) and the dopamine transporter (DAT) ligand [(11)C]FECIT to measure loss of nigrostriatal dopaminergic neurons in early phase of early onset (EOPD) and late onset Parkinsons disease (LOPD). The analysis was carried out with both regions of interest and voxelwise method (SPM2), at group and single subject levels. Genetic analysis tested for the mutations occurring most frequently in Caucasian population. A significant, bilateral, asymmetric DAT reduction was observed in both EOPD and LOPD. Noteworthy, the side and severity of DAT binding reduction significantly correlated with the severity and asymmetry of motor clinical scores. The two EOPD patients carrying mutations in the PARK2 and PARK6 genes, respectively, displayed the lowest values, bilaterally. This work demonstrates that severity of nigrostriatal damage in early disease phase of sporadic PD is not dependent on age at onset. Genetically determined PD is associated with more severe and widespread dopaminergic impairment.


Journal of Alzheimer's Disease | 2012

[11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis.

Alessandra Marcone; Valentina Garibotto; Rosa Maria Moresco; Ioana Florea; Andrea Panzacchi; Assunta Carpinelli; Jere Virta; Marco Tettamanti; Barbara Borroni; Alessandro Padovani; Alessandra Bertoldo; Karl Herholz; Juha O. Rinne; Stefano F. Cappa; Daniela Perani

Non-invasive approaches for positron emission tomography (PET) parametric imaging of acetylcholinesterase (AChE) activity have been developed and applied to the investigation of dementia, mainly Alzheimers disease (AD), but also dementia with Lewy bodies (DLB), not including, however, patients in the early disease stage. The few cholinergic PET studies on mild cognitive impairment (MCI) did not provide clinical follow-up. One limitation of the methods used so far is the relatively low sensitivity in measuring subcortical or deep cortical structures, which might represent specific disease markers. Here we assessed AChE activity with [11C]-MP4A and PET by a maximum a posteriori Bayesian method (MAPB) based on a 2-tissue compartment-3-rate-constant reference region model. 30 subjects were included: 10 multi-domain amnestic MCI (aMCI) with a follow up of 2 years, 7 probable AD (pAD), 4 DLB subjects, and 9 healthy controls. Regions of interest and voxel-based statistical parametric mapping analyses revealed significant and widespread AChE reductions in several cortical regions and in the hippocampus in all pAD subjects and aMCI subjects who progressed to AD (converters). Noteworthy, hippocampal AChE activity correlated significantly with long-term verbal and non-verbal memory in both aMCI converters and pAD. The pattern was more heterogeneous in early DLB patients, with only 2 out of 4 cases showing a severe or intermediate reduction of AChE activity. The comparable AChE reductions in pAD and aMCI converters indicate the presence of a widespread impairment of the cholinergic system already in the MCI phase. A more variable degree of cholinergic dysfunction is present in early DLB.


Journal of Medicinal Chemistry | 2000

Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography

Sergio Todde; Rosa Maria Moresco; Pasquale Simonelli; Pier Giovanni Baraldi; Barbara Cacciari; Giampiero Spalluto; Katia Varani; Angela Monopoli; Mario Matarrese; Assunta Carpinelli; Fulvio Magni; Marzia Galli Kienle; Ferruccio Fazio


The Journal of Nuclear Medicine | 1994

Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12

Claudio Rossetti; Giovanna Vanoli; Giovanni Paganelli; Marek Kwiatkowski; Felicia Zito; Fabio Colombo; Chiara Bonino; Assunta Carpinelli; Rosangela Casati; Karen F. Deutsch; Mary Marmion; Steven R. Woulfe; Fabio Lunghi; Edward Deutsch; Ferruccio Fazio


Journal of Medicinal Chemistry | 2001

Labeling and evaluation of N-[11C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors.

Mario Matarrese; Rosa Maria Moresco; Andrea Cappelli; Maurizio Anzini; Salvatore Vomero; Pasquale Simonelli; Elisa Verza; Fulvio Magni; Francesco Sudati; Dmitri Soloviev; Sergio Todde; Assunta Carpinelli; Marzia Galli Kienle; Ferruccio Fazio


NeuroImage | 2008

MAP vs RLS methods for [11C]MP4A PET pixel-wise quantification in neurodegenerative diseases discrimination

Ioana Florea; Alessandra Bertoldo; R.M. Moresco; Assunta Carpinelli; Andrea Panzacchi; Valentina Garibotto; S. Iannaccone; Daniela Perani; M. C. Gilardi; Claudio Cobelli; F. Fazio

Collaboration


Dive into the Assunta Carpinelli's collaboration.

Top Co-Authors

Avatar

Rosa Maria Moresco

University of Milano-Bicocca

View shared research outputs
Top Co-Authors

Avatar

Daniela Perani

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Andrea Panzacchi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Ferruccio Fazio

University of Milano-Bicocca

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mario Matarrese

University of Milano-Bicocca

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge